We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+7.83%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$2.92B
AUM Growth
-$347M
Cap. Flow
-$416M
Cap. Flow %
-14.23%
Top 10 Hldgs %
63.83%
Holding
68
New
13
Increased
7
Reduced
7
Closed
4

Top Buys

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$75.9M
2
VRDN icon
Viridian Therapeutics
VRDN
+$32M
3
MBX
MBX Biosciences
MBX
+$26.9M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$23.3M
5
RLAY icon
Relay Therapeutics
RLAY
+$18.7M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$222M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$170M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$153M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$30.5M
5
ITOS
iTeos Therapeutics
ITOS
+$25M

Sector Composition

Rank Sector Weight
1 Healthcare 99.84%
2 Miscellaneous 0.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
1
DELISTED
Apellis Pharmaceuticals
APLS
$343M 11.74%
11,890,843
+283,418
+2% +$10.5M
ANAB icon
2
AnaptysBio
ANAB
$1.67B
$261M 8.94%
7,794,996
+273,972
+4% +$9.36M
CRNX icon
3
Crinetics Pharmaceuticals
CRNX
$9B
$219M 7.5%
4,288,120
+132,745
+3% +$6.85M
PRTA icon
4
Prothena Corp
PRTA
$479M
$194M 6.63%
11,584,280
– –
JAZZ icon
5
Jazz Pharmaceuticals
JAZZ
$15.9B
$190M 6.51%
1,706,469
+692,517
+68% +$75.9M
ZYME icon
6
Zymeworks
ZYME
$2.02B
$169M 5.77%
13,437,473
– –
ARVN icon
7
Arvinas
ARVN
$600M
$166M 5.67%
6,726,491
– –
KURA icon
8
Kura Oncology
KURA
$1.13B
$113M 3.88%
5,806,871
– –
XNCR icon
9
Xencor
XNCR
$1.94B
$107M 3.67%
5,330,416
– –
TNGX icon
10
Tango Therapeutics
TNGX
$3.94B
$103M 3.51%
13,330,736
– –
JANX icon
11
Janux Therapeutics
JANX
$1.1B
$66.8M 2.29%
1,469,818
– –
CRSP icon
12
CRISPR Therapeutics
CRSP
$5.58B
$65.3M 2.23%
1,389,276
– –
IMNM icon
13
Immunome
IMNM
$3.13B
$56.7M 1.94%
3,879,415
– –
NGNE icon
14
Neurogene
NGNE
$732M
$53.3M 1.83%
1,271,342
– –
CNTA
15
DELISTED
Centessa Pharmaceuticals
CNTA
$51.5M 1.76%
3,223,851
-2,490,553
-44% -$30.5M
VRDN icon
16
Viridian Therapeutics
VRDN
$2.61B
$44.6M 1.53%
+1,958,847
New +$32M
NUVB icon
17
Nuvation Bio
NUVB
$2.34B
$44M 1.51%
19,209,643
– –
THRD
18
DELISTED
Third Harmonic Bio
THRD
$43.1M 1.48%
3,182,444
– –
PCVX icon
19
Vaxcyte
PCVX
$8.9B
$40.3M 1.38%
352,464
+52,464
+17% +$4.73M
MRSN
20
DELISTED
Mersana Therapeutics
MRSN
$36.6M 1.25%
774,588
– –
ORIC icon
21
Oric Pharmaceuticals
ORIC
$1.37B
$35M 1.2%
3,418,068
– –
RNAM
22
DELISTED
Avidity Biosciences
RNAM
$34.8M 1.19%
757,576
– –
EWTX icon
23
Edgewise Therapeutics
EWTX
$4.64B
$33.4M 1.14%
1,250,385
– –
MBX
24
MBX Biosciences
MBX
$3.03B
$30.5M 1.05%
+1,175,809
New +$26.9M
NMRA icon
25
Neumora Therapeutics
NMRA
$261M
$27.4M 0.94%
2,071,450
– –
1
2 3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q3 2024 Portfolio in Review

As of Q3 2024, EcoR1 Capital held 68 positions worth $2.92B, down 11% from $3.27B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

EcoR1 Capital withdrew a net $416M in Q3 2024, closing 4 positions and reducing 7 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $222M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, EcoR1 Capital opened a new position in Viridian Therapeutics worth $44.6M.

  • EcoR1 Capital's largest Q3 2024 buy was Viridian Therapeutics: 1,958,847 shares worth $44.6M.
  • EcoR1 Capital added most to Jazz Pharmaceuticals in Q3 2024, an estimated $75.9M increase.
  • EcoR1 Capital's biggest Q3 2024 reduction was Lakefront Biotherapeutics American Depositary Shares, cutting an estimated $153M.
  • EcoR1 Capital fully exited Sarepta Therapeutics in Q3 2024, selling an estimated $222M.
  • EcoR1 Capital's ten largest holdings make up 64% of its $2.92B portfolio in Q3 2024.
  • EcoR1 Capital opened 13 new positions and closed 4 in Q3 2024.
  • EcoR1 Capital's portfolio value fell 11% quarter-over-quarter to $2.92B.

Based on EcoR1 Capital's 13F filing for Q3 2024, filed 14 Nov 2024.